加载中
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
前收盘价
US$8.77
+US$0.64 · +7.87%
盘中时间采用ET。市场数据可能有所延迟。
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
日内区间
当前US$8.77
52周区间
当前US$8.77
盘中时间采用ET。市场数据可能有所延迟。
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
日内区间
当前US$8.77
52周区间
当前US$8.77
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 281.5万 USD | 698.3万 USD | 802.1万 USD | 956.1万 USD | 913.35万 USD |
| 销售、一般及管理费用 | 928万 USD | 966.4万 USD | 1135.6万 USD | 1352.7万 USD | 808.07万 USD |
| 营业费用 | 1727.5万 USD | 2164.3万 USD | 1680.6万 USD | 2308.8万 USD | 1721.41万 USD |
| 利息收入 | 1000 USD | 8000 USD | 8.2万 USD | 4.59万 USD | 1.06万 USD |
| 利息支出 | 94.9万 USD | −24.4万 USD | — | — | — |
| 折旧和摊销 | — | 1.4万 USD | 4000 USD | 4000 USD | 4126 USD |
| 营业利润 | −1727.5万 USD | −2164.3万 USD | −1680.6万 USD | −2308.8万 USD | −1721.41万 USD |
| 净利润 | −1729.8万 USD | −1979.1万 USD | −1000.8万 USD | −1774.8万 USD | −1742.42万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$24.75
上涨空间 182.21%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年3月31日 | 1:40 | — | — |
股票拆分 | 2023年8月17日 | 1:20 | — | — |
股票拆分 | 2015年9月17日 | 1:10 | — | — |
股票拆分 | 2014年1月3日 | 1:5 | — | — |
已生效 2026年3月31日
1:40
已生效 2023年8月17日
1:20
已生效 2015年9月17日
1:10
已生效 2014年1月3日
1:5
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
